Hypothesis

Core proposition: Age-associated senescence of follicular dendritic cells (FDCs) reduces CXCL13 production, which limits B cell entry and survival in germinal centers (GCs) and thereby lowers activation-induced cytidine deaminase (AID) expression extrinsically. Although aged B cells retain the intrinsic ability to differentiate into plasma cells and proliferate when stimulated in vitro 3, the aged microenvironment fails to deliver the CD40L, IL-21 and BAFF signals that sustain AID and sustain somatic hypermutation (SHM) 2. This failure is amplified by B cell-intrinsic insulin receptor signaling, which drives a senescent phenotype in FDCs via exosomal miR-155 transfer, creating a feedback loop that further depresses CXCL13 and GC output 4.

Mechanistic rationale

1. FDC CXCL13 decline – Aging lowers FDC numbers and disrupts follicle architecture 2. CXCL13 is the chief chemokine that pulls CXCR5+ B cells into the GC light zone; less CXCL13 means fewer B cells receive tonic BCR and CD40 signals that induce AID via NF-κB and IRF4 pathways.

2. B cell insulin receptor (InsR) signaling – In aged mice, B cells show heightened InsR activity that correlates with CD4 T cell dysfunction 4. We propose that InsR activation increases secretion of exosomes enriched in miR-155, which is taken up by FDCs and suppresses CXCL13 transcription through direct targeting of its 3′-UTR.

3. Extrinsic AID suppression – Reduced CXCR5 signaling lowers calcium flux and downstream PKCβ activation, diminishing the induction of AID and its co‑factor E47. This explains the observed drop in replacement mutations in CDR1/2 of heavy chains and the accompanying CDR3 lengthening in light chains 1.

Testable predictions

• Prediction 1: Conditional deletion of the insulin receptor in B cells (InsR^fl/fl CD19‑Cre) in aged mice will restore FDC CXCL13 levels, increase GC B cell frequency, and rescue SHM rates to those seen in young mice.
• Prediction 2: Administering recombinant CXCL13 or overexpressing CXCL13 specifically in FDCs (using Ccl19‑Cre CXCL19 transgene) in aged wild-type mice will increase AID expression in GC B cells and improve affinity maturation without altering B cell intrinsic proliferation.
• Prediction 3: Transferring exosomes isolated from InsR-high aged B cells into young mice will recapitulate the aged phenotype: reduced FDC CXCL13, fewer GCs, and lower SHM, an effect blocked by antisense inhibition of miR-155 in FDCs.
• Prediction 4: Blocking CD40L or IL-21 signaling in young mice will mimic the aged extrinsic defect, demonstrating that the microenvironmental cues are sufficient to suppress AID even when B cell intrinsic machinery is intact.

Experimental approach

• Use flow cytometry to quantify CXCR5+ GC B cells, FDC numbers (CD35+), and intracellular AID in spleen and lymph nodes of young (3 mo) and aged (20 mo) mice under each genetic or pharmacologic manipulation.
• Measure SHM frequency by sequencing IgV genes from sorted GC B cells, focusing on replacement vs. silent mutations in CDR regions.
• Assess serum antibody affinity using ELISA with decreasing antigen concentrations or surface plasmon resonance.
• Exosome profiling: isolate B cell-derived exosomes, quantify miR-155 by qRT-PCR, and test uptake by FDC cultures using fluorescent labels.
• Rescue experiments: administer anti-miR-155 liposomes targeting FDCs or CXCL13-Fc fusion protein and monitor GC output.

If any of the predictions fail—e.g., InsR deletion in B cells does not restore CXCL13 or SHM—the hypothesis would be falsified, indicating that B cell-intrinsic insulin signaling does not drive FDC senescence via exosomal miR-155. Conversely, confirmation would support a model where extrinsic stromal collapse, orchestrated by aged B cell metabolic signaling, is the primary limiter of antibody quality in aging.